Humira’s Strong Growth Is A Double-Edged Sword For AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Gonzalez says Humira will remain a growth leader past its 2015 expiry in U.S. In HCV, Viekira Pak gets off to a solid start, as AbbVie points to ramping U.S. sales in second half, faster-than-expected progress in EU.